Cryo-Cell International's Stem Cell Research and Development Helps the Fight Against Breast Cancer
06 Octobre 2009 - 2:27PM
PR Newswire (US)
Ongoing Initiatives Include Research Partnership with National
Institutes of Health to Study C'elle Menstrual Blood Stem Cells
OLDSMAR, Fla., Oct. 6 /PRNewswire-FirstCall/ -- Cryo-Cell
International, a global leader in stem cell innovation, is proud to
be making progress in the fight against breast cancer through
research and development using stem cells from menstrual blood. In
honor of National Breast Cancer Awareness Month, Cryo-Cell is
supporting Susan G. Komen for the Cure® through C'elle®, the
company's service which enables women to collect and cryopreserve
stem cells from their menstrual blood. Cryo-Cell is currently in a
research partnership with the National Institutes of Health (NIH)
Clinical Center, where research is underway to better understand
the C'elle stem cells and their potential benefit for the treatment
of breast cancer. Stem cells from menstrual blood are proven to be
a rich source of stem cells which proliferate rapidly and have the
ability to become many different types of cells. Since launching
its proprietary service nearly two years ago, the company continues
to expand research and development initiatives in order to
accelerate the potential diagnostic and therapeutic benefits of
these unique stem cells. According to the American Cancer Society,
there are 2.5 million breast cancer patients and survivors today,
and an estimated one in eight women will be stricken with this
disease at some point in her life. As a part of Cryo-Cell's
commitment to finding treatments for breast cancer and to celebrate
the promise of C'elle stem cells, the company is donating $25 to
Susan G. Komen for the Cure for every enrollment in the C'elle
service, and $50 for every enrollment in its Protect Baby Protect
Mom(SM) package throughout the month of October. "We at Cryo-Cell
continue to dedicate significant resources toward the fight against
breast cancer, and emerging science is very promising," said
Cryo-Cell CEO Mercedes Walton. "Through our partnership with the
National Institutes of Health, it is exciting to have such an
integral role in research to understand how C'elle stem cells might
help to treat breast cancer. I continue to be inspired by all of
the strong and courageous women out there who fight this disease,
so it's an honor to support Susan G. Komen for the Cure," she
added. Susan G. Komen for the Cure is the world's largest
grassroots network of breast cancer survivors and activists and has
invested more than $1 billion since inception in 1982. A pioneer in
the non-controversial stem cell arena with its U-Cord® service for
collection and cryopreservation of cord blood stem cells, Cryo-Cell
has served nearly 185,000 clients worldwide. Stem cells from
umbilical cord blood treat more than 75 diseases today, including
sickle cell disease, several types of acute and chronic leukemias,
Non-Hodgkin's lymphoma, and Hodgkin's disease. Emerging science
shows great promise for potential treatments including spinal cord
injury, heart disease, breast cancer, stroke, diabetes, Parkinson's
disease, Alzheimer's disease and many more. For more information,
or to schedule an interview with Cryo-Cell International
executives, please contact Monica Kozak at (203) 545-1055; . About
C'elle The C'elle(SM) service was introduced in November 2007 as
the first and only service that empowers women to collect and
cryopreserve menstrual flow containing undifferentiated adult stem
cells for future utilization by the donor or possibly their
first-degree relatives in a manner similar to umbilical cord blood
stem cells. For more information, visit http://www.celle.com/.
About Cryo-Cell International, Inc. (OTC:CCEL) (BULLETIN BOARD:
CCEL) Based in Oldsmar, Florida, with nearly 185,000 clients
worldwide, Cryo-Cell is a global leader in stem cell innovation.
ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell
operates in a state-of-the-art Good Manufacturing Practice and Good
Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a
publicly traded company. OTC Bulletin Board Symbol: CCEL. For more
information, please call 1-800-STOR-CELL (1-800-786-7235) or visit
http://www.cryo-cell.com/. DATASOURCE: Cryo-Cell International,
Inc. CONTACT: Monica Kozak, +1-203-545-1055, , for Cryo-Cell
International, Inc. Web Site: http://www.cryo-cell.com/
Copyright